Posts

Showing posts with the label Nuclear Medicine Market Revenue

Nuclear Medicine Market Size Is Expected To Reach USD 22.3 Billion By 2030

Image
  San Francisco, 17 Nov 2023:  The Report   Nuclear Medicine Market  Size, Share & Trends Analysis Report By Product (Diagnostics (SPECT, PET), Therapeutics (Alpha Emitters, Beta Emitters, Brachytherapy)), By Application, By End-use, By Region, And Segment Forecasts, 2023 - 2030 The global nuclear medicine market size is expected to reach USD 22.3 billion by 2030, registering a CAGR of 11.8% over the forecast period, according to a new report by Grand View Research, Inc. The increasing prevalence of chronic diseases such as cancer & thyroid is anticipated to drive market growth. The impending approval of multiple radiopharmaceutical therapeutics during the forecast period will be a major driver for the market. For instance, in March 2022, Novartis AG received approval for Pluvicto (Lu 177) for the treatment of adult patients with prostate cancer. According to the Pan American Health Organization (PAHO), in 2022, globally around 20 million new cases of cancer are estimated to be

Nuclear Medicine Market Expected To Trigger A Revenue To USD 15.2 Billion By 2025 : Grand View Research Inc.

San Francisco, 14  August 2019:   The Report   Nuclear Medicine Market   Size, Share & Trends Analysis Report By Product (Diagnostics, Therapeutics), By Application, By Region (North America, APAC, Europe), And Segment Forecasts, 2018 – 2025 The global radiopharmaceuticals/nuclear medicine market size is expected to reach USD 15.2 billion by 2025, according to a new report by Grand View Research, Inc., registering a 10.1% CAGR during the forecast period. The burden of chronic diseases such as cancer and cardiac disorders is on a rise. Nuclear medicine is widely used for diagnosis as well as treatment of such disorders. Increasing prevalence of these disorders has a direct impact on usage of radiopharmaceuticals. As per data published by the World Health Organization (WHO), cancer is the second leading cause of death around the globe and in 2015, accounted for 8.8 million deaths. This is anticipated to drive demand for radiopharmaceuticals in the years to come. Diagnostics, w